BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

509 related articles for article (PubMed ID: 8727604)

  • 1. Usefulness of simultaneous determination of alpha-fetoprotein and des-gamma-carboxy prothrombin in hepatocellular carcinoma.
    Nakao A; Taniguchi K; Inoue S; Harada A; Nonami T; Watanabe K; Takagi H
    Semin Surg Oncol; 1996; 12(3):160-3. PubMed ID: 8727604
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Serum levels of des-gamma-carboxy prothrombin measured using the revised enzyme immunoassay kit with increased sensitivity in relation to clinicopathologic features of solitary hepatocellular carcinoma.
    Okuda H; Nakanishi T; Takatsu K; Saito A; Hayashi N; Takasaki K; Takenami K; Yamamoto M; Nakano M
    Cancer; 2000 Feb; 88(3):544-9. PubMed ID: 10649245
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Measurement of serum levels of des-gamma-carboxy prothrombin in patients with hepatocellular carcinoma by a revised enzyme immunoassay kit with increased sensitivity.
    Okuda H; Nakanishi T; Takatsu K; Saito A; Hayashi N; Watanabe K; Magario N; Yokoo T; Naraki T
    Cancer; 1999 Feb; 85(4):812-8. PubMed ID: 10091758
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical significance of abnormal prothrombin (DCP) in relation to postoperative survival and prognosis in patients with hepatocellular carcinoma.
    Inoue S; Nakao A; Harada A; Nonami T; Takagi H
    Am J Gastroenterol; 1994 Dec; 89(12):2222-6. PubMed ID: 7526679
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical significance of simultaneous determinations of alpha-fetoprotein and des-gamma-carboxy prothrombin in monitoring recurrence in patients with hepatocellular carcinoma.
    Aoyagi Y; Oguro M; Yanagi M; Mita Y; Suda T; Suzuki Y; Hata K; Ichii K; Asakura H
    Cancer; 1996 May; 77(9):1781-6. PubMed ID: 8646674
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Serum des-gamma-carboxyprothrombin level by a modified enzyme immunoassay method in hepatocellular carcinoma: clinical significance in small hepatocellular carcinoma.
    Soga K; Watanabe T; Aikawa K; Toshima M; Shibasaki K; Aoyagi Y
    Hepatogastroenterology; 1998; 45(23):1737-41. PubMed ID: 9840138
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Determination of serum des-gamma-carboxy prothrombin levels in patients with small-sized hepatocellular carcinoma: comparison of the conventional enzyme immunoassay and two modified methods.
    Nomura F; Ishijima M; Horikoshi A; Nakai T; Ohnishi K
    Am J Gastroenterol; 1996 Jul; 91(7):1380-3. PubMed ID: 8677999
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Sequential fluctuation pattern of serum des-gamma-carboxy prothrombin levels detected by high-sensitive electrochemiluminescence system as an early predictive marker for hepatocellular carcinoma in patients with cirrhosis.
    Shimizu A; Shiraki K; Ito T; Sugimoto K; Sakai T; Ohmori S; Murata K; Takase K; Tameda Y; Nakano T
    Int J Mol Med; 2002 Mar; 9(3):245-50. PubMed ID: 11836630
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Des-gamma-carboxyprothrombin, alpha-fetoprotein and AFP-L3 in patients with chronic hepatitis, cirrhosis and hepatocellular carcinoma.
    Durazo FA; Blatt LM; Corey WG; Lin JH; Han S; Saab S; Busuttil RW; Tong MJ
    J Gastroenterol Hepatol; 2008 Oct; 23(10):1541-8. PubMed ID: 18422961
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Significance of alpha-fetoprotein and des-gamma-carboxy prothrombin in patients with hepatocellular carcinoma undergoing hepatectomy.
    Yamamoto K; Imamura H; Matsuyama Y; Hasegawa K; Beck Y; Sugawara Y; Makuuchi M; Kokudo N
    Ann Surg Oncol; 2009 Oct; 16(10):2795-804. PubMed ID: 19669841
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Usefulness of determining a protein induced by vitamin K absence in detection of hepatocellular carcinoma.
    Cui R; Wang B; Ding H; Shen H; Li Y; Chen X
    Chin Med J (Engl); 2002 Jan; 115(1):42-5. PubMed ID: 11930656
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical evaluation of plasma abnormal prothrombin (des-gamma-carboxy prothrombin) in hepatobiliary malignancies and other diseases.
    Nakao A; Suzuki Y; Isshiki K; Kimura Y; Takeda S; Kishimoto W; Nonami T; Harada A; Takagi H
    Am J Gastroenterol; 1991 Jan; 86(1):62-6. PubMed ID: 1702578
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Clinical usefulness of plasma PIVKA-II assay and its limitations in patients with hepatocellular carcinoma].
    Fujiyama S; Morishita T; Shibata J; Sato T
    Gan To Kagaku Ryoho; 1989 Apr; 16(4 Pt 2-1):1129-38. PubMed ID: 2471453
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Utility of Lens culinaris agglutinin-reactive fraction of alpha-fetoprotein and des-gamma-carboxy prothrombin, alone or in combination, as biomarkers for hepatocellular carcinoma.
    Sterling RK; Jeffers L; Gordon F; Venook AP; Reddy KR; Satomura S; Kanke F; Schwartz ME; Sherman M
    Clin Gastroenterol Hepatol; 2009 Jan; 7(1):104-13. PubMed ID: 18849011
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Sensitive measurement of serum abnormal prothrombin (PIVKA-II) as a marker of hepatocellular carcinoma.
    Tanaka Y; Kashiwagi T; Tsutsumi H; Nagasawa M; Toyama T; Ozaki S; Naito M; Ishibashi K; Azuma M
    Hepatogastroenterology; 1999; 46(28):2464-8. PubMed ID: 10522021
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Serum des-gamma-carboxy prothrombin levels determined by a new generation of sensitive immunoassays in patients with small-sized hepatocellular carcinoma.
    Nomura F; Ishijima M; Kuwa K; Tanaka N; Nakai T; Ohnishi K
    Am J Gastroenterol; 1999 Mar; 94(3):650-4. PubMed ID: 10086646
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Sensitivity and specificity of des-gamma-carboxy prothrombin for diagnosis of patients with hepatocellular carcinomas varies according to tumor size.
    Nakamura S; Nouso K; Sakaguchi K; Ito YM; Ohashi Y; Kobayashi Y; Toshikuni N; Tanaka H; Miyake Y; Matsumoto E; Shiratori Y
    Am J Gastroenterol; 2006 Sep; 101(9):2038-43. PubMed ID: 16848811
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Use of serum PIVKA-II (DCP) determination for differentiation between benign and malignant liver diseases.
    Lamerz R; Runge M; Stieber P; Meissner E
    Anticancer Res; 1999; 19(4A):2489-93. PubMed ID: 10470180
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Optimal cut-off value of PIVKA-II for diagnosis of hepatocellular carcinoma--using ROC curve].
    Kim MJ; Bae KW; Seo PJ; Jeong IK; Kim JH; Lee BH; Bang KT; Kim DW; Song IH
    Korean J Hepatol; 2006 Sep; 12(3):404-11. PubMed ID: 16998292
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Diagnostic and prognostic value of alpha-fetoprotein, des-γ-carboxy prothrombin and squamous cell carcinoma antigen immunoglobulin M complexes in hepatocellular carcinoma.
    Bertino G; Neri S; Bruno CM; Ardiri AM; Calvagno GS; Malaguarnera M; Toro A; Malaguarnera M; Clementi S; Bertino N; Di Carlo I
    Minerva Med; 2011 Oct; 102(5):363-71. PubMed ID: 22193346
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 26.